Fröhling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6):501-13. doi:10.1016/j.ccr.2007.11.005
Antipova AA, Stockwell BR, Golub TR. Gene expression-based screening for inhibitors of PDGFR signaling. Genome Biol. 2008;9(3):R47. doi:10.1186/gb-2008-9-3-r47
Tam WF, Gu TL, Chen J, et al. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood. 2008;112(5):1981-92. doi:10.1182/blood-2007-07-103010
Ong SE, Schenone M, Margolin AA, et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009;106(12):4617-22. doi:10.1073/pnas.0900191106
Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377. doi:10.1038/ncomms7377
Gannon HS, Kaplan N, Tsherniak A, et al. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016;14(2):207-15. doi:10.1158/1541-7786.MCR-15-0321
Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262-9. doi:10.1038/nm.4040
Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374(1):54-61. doi:10.1056/NEJMoa1508887
Seashore-Ludlow B, Rees MG, Cheah JH, et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov. 2015;5(11):1210-23. doi:10.1158/2159-8290.CD-15-0235
Chetty S, Engquist EN, Mehanna E, Lui KO, Tsankov AM, Melton DA. A Src inhibitor regulates the cell cycle of human pluripotent stem cells and improves directed differentiation. J Cell Biol. 2015;210(7):1257-68. doi:10.1083/jcb.201502035